First Myeloma CAR T-cell Therapy Phase 2 Trial Opens Enrollment
The U.S. Food and Drug Administration (FDA) has granted Celgene and Bluebird Bio’s bb2121 — the first CAR T-cell therapy for multiple myeloma —…
Myeloma
FDA Allows Trials of Opdivo Combo Therapy to Resume, Signaling No New Safety Concerns
The U.S. Food and Drug Administration (FDA) agreed to allow two clinical trials of Opdivo (nivolumab)-based combinations for myeloma to resume, after being put on partial…
Ascentage Gets FDA Nod to Advance APG-1387 into Clinical Trials for Myeloma, Other Cancers
The U.S. Food and Drug Administration (FDA) has accepted Ascentage Pharma‘s Investigational New Drug (IND) application for APG-1387, allowing Ascentage to test the…
CAR T-cells Targeting Integrin β7 Protein Show Promise in Countering Multiple Myeloma Cells
A Japanese study has found that an active structure of the protein integrin β7 is specific to multiple myeloma cells, suggesting that it could be…
First Patient-led Crowdfunding Initiative for Multiple Myeloma Research Tops $500,000 to Fund Two Projects
The first patient-led crowdsourcing and crowdfunding initiative for multiple myeloma (MM) research has exceeded its goal of raising $500,000 to advance new…
Janssen Seeks US Approval of Darzalex Combo for Newly Diagnosed Multiple Myeloma
Janssen Pharmaceuticals has requested the U.S. Food and Drug Administration (FDA) add a new indication for Darzalex (daratumumab) in combination with other therapies…
Multiple Myeloma Research Foundation Holds First Patient Summit in Denver
The first-ever Multiple Myeloma Research Foundation (MMRF) Patient Summit was held March 25 in Denver to help patients and caregivers learn more about…
New Cancer Drug-delivery Vehicle May Provide More Precise Treatment, Study Shows
Antibody-drug conjugates (ADCs), a class of drugs in which a cancer-targeting therapy is attached to a specific monoclonal antibody without harming healthy cells, continue to…
BioLineRx’s BL-8040 Shows Promise in Bone Marrow Transplants for Blood Cancers
BioLineRx’s investigational drug BL-8040 has demonstrated positive interim results from a Phase 2 trial as a monotherapy for the mobilization and collection of donor blood stem…
Experimental LCL161 Combo Therapy Boosts Immunity and Shrinks Tumors in Myeloma Patients
By activating the immune system, the experimental drug LCL161 has the potential to fight myeloma in both mice and humans, according to a new study by…
